
Meiji Seika Pharma Begins Phase I Trial of ME3241 in Australia
Meiji Seika Pharma Co., Ltd. has announced the initiation of a Phase I clinical trial for ME3241, an innovative anti-PD-1 agonist monoclonal antibody developed through a research collaboration with the Foundation for Biomedical Research and Innovation at Kobe (FBRI). The…












